Clinical Trial Update: First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update reports completion of a study evaluating first-line pazopanib in poor-risk patients with metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: iOMEDICO AG | Conditions: Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell | Phase 4 | Status: COMPLETED